Novo Nordisk’s Bio Innovation Hub is a research & development (R&D) unit designed to bring life science innovation to life through collaborative partnerships with biotechs and academics.
We bring more than just funding into our partnerships - we provide a deep disease understanding. Backed by an over 100-year history in life science innovation, we take translational and drug development capabilities and accelerate the process of bringing innovative ideas into the hands of people living with chronic diseases.
Our strategic focus lies within cardiometabolic, rare endocrine and blood disorders. We aspire not only to treat diseases, but also to reverse, cure and prevent them. Through exploring new modalities and new types of therapies, we believe this is possible.
Based in the heart of Cambridge, Massachusetts, one of the world’s most vibrant life science ecosystems, the Novo Nordisk Bio Innovation Hub puts forward access to the knowledge and resources innovators need to take their ideas to the next level.
The Novo Nordisk Bio Innovation Hub combines the reach of a global
biopharmaceutical leader with the keen eye of a biotech to co-create
breakthrough ideas that will change the way we treat disease.
Leveraging Novo Nordisk’s centennial legacy of bringing life-changing
medicines to patients, we help others fill the gaps in the drug
development process by connecting experts with ideas.
Our Bio Innovation Hub is a Transformational Research Unit within our larger Research and Early Development (R&ED) organization. This provides us the autonomy to operate at the speed of a start up, but the stability and expertise of a global R&D network. Our Hub’s team consists of multi-disciplinary experts in diverse fields, including: disease biology, medical devices, peptide & medicinal chemistry, bioinformatics, and pre-clinical and clinical drug development. All of our experts are working to find the best way to work together to develop your idea.
Our strategic focus lies within cardiometabolic diseases, include: diabetes, obesity, cardiovascular disease, chronic kidney disease, and NASH - as well as rare diseases like growth-related disorders, hemophilia and rare blood disorders, Alzheimer’s, Parkinson’s, and Sickle cell disease.
We aspire not only to treat these diseases, but to reverse, cure and prevent them. Through exploring new modalities and new types of therapies, we believe this is possible.
Innovative technologies that enable and enhance treatments are needed to support research. They are also required for the development and production of therapeutics. We are interested in co-creating solutions that include:
- Novel biomarker approaches - better identification of specific patient segments, disease prediction and progression
- Data
and digital science - chemical, molecular, preclinical, and patient
models that can reduce the time and the number of iterations needed
to develop a new therapeutic
- Devices and delivery solutions - improvements to convenience, affordability, sustainability, and adherence to treatments, including digital health solutions.
